Agnete Witness Praest Jensen

Medicine & Life Sciences

1. Tumor-Infiltrating Lymphocytes 100%
2. Immunotherapy 84%
3. Melanoma 67%
4. Cell- and Tissue-Based Therapy 64%
5. Neoplasms 53%
6. tocilizumab 47%
7. Ipilimumab 47%
8. Nivolumab 45%
9. T-Lymphocytes 42%
10. Histocompatibility Antigens Class I 39%
11. Radiosurgery 37%
12. Antigen Presentation 36%
13. Janus Kinase 1 36%
14. Adrenergic Agents 32%
15. Pancreatic Neoplasms 31%
16. Proteomics 31%
17. beta 2-Microglobulin 30%
18. Phenotype 29%
19. Immunity 27%
20. Direction compound 24%
21. Antigens 21%
22. Adrenergic Receptors 21%
23. Exercise 14%
24. Therapeutics 12%
25. Confidence Intervals 12%
26. Lymphocyte Activation 12%
27. Clinical Trials 11%
28. Tumor Microenvironment 10%
29. Mass Spectrometry 8%
30. Signal Transduction 8%
31. gemcitabine 7%
32. Major Histocompatibility Complex 7%
33. Proteins 7%
34. Western World 6%
35. Exercise Therapy 6%
36. Fluorouracil 6%
37. Tumor Escape 6%
38. Survival 6%
39. Progression-Free Survival 6%
40. Epinephrine 5%
41. Interleukin-6 5%
42. Radiation 5%
43. Longevity 5%